MolDX: Genetic Testing for Heritable Thoracic Aortic Disease

Genetic testing for heritable thoracic aortic disease is covered for hereditary germline tests (LDT, FDA-cleared, or FDA-approved, including NGS) when the patient has aortic root or ascending aortic dilation/aneurysm/dissection and at least one qualifying feature (presentation <60 years, syndromic features, family history of aortic/peripheral/intracranial aneurysm, or family history of unexplained young sudden death). Coverage requires documentation that genetic counseling was offered, that the test includes the minimum ClinGen/ACC-AHA–recommended gene/variant content that can be detected by the assay, and that the test has completed a MolDX Technical Assessment; tests with unvalidated or unclear-content and those conflicting with repeat-testing policy L38353 are not covered.

"Patient presents with aortic root or ascending aortic dilation, aneurysm, or dissection as defined by national consensus guidelines."